By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
Panelists agree that Novartis (NVS) has successfully pivoted to a higher-margin growth trajectory, driven by Kisqali, Kesimpta, and Pluvicto. However, they disagree on the sustainability of its growth and valuation, with some citing the upcoming Entresto patent cliff and intense competition in the CDK4/6 space as significant headwinds.
Risk: The upcoming Entresto patent cliff and intense competition in the CDK4/6 space, which could slow down the growth of key drugs like Kisqali and Pluvicto.
Opportunity: The potential for Kisqali to capture significant market share from Lilly's Verzenio and the optionality of the pipeline, which could sustain free cash flow even as Entresto decays.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
We just covered the 14 Best Low Risk High Growth Stocks to Buy Right Now and Novartis AG (NYSE:NVS) ranks 7th on this list.
Following the successful spin-off of its Sandoz generics division in late 2023, Novartis AG (NYSE:NVS) has transformed into a high-margin, pure-play innovative medicines company that is currently outpacing its peers in both pipeline velocity and capital efficiency. In early 2026, Novartis reported that its core growth drivers, Kisqali (breast cancer), Kesimpta (multiple sclerosis), and Pluvicto (radioligand therapy), were seeing explosive growth. Specifically, Kisqali sales surged by 57% and Pluvicto by 42% in constant currencies, providing the high-growth kicker that elite investors look for. The firm has built a massive competitive moat in radioligand therapy. With the FDA-approved Millburn facility scaling up in early 2026, the company is effectively the leader of this high-margin cancer treatment niche.
READ ALSO: D. E. Shaw Stock Portfolio: Top 10 Stocks to Buy.
Novartis AG (NYSE:NVS) stock offers utility-like safety combined with tech-like margins. The company achieved a 40.1% core operating margin in 2025/2026, an elite figure that provides a massive buffer against inflationary pressures and R&D costs. It generated $17.6 billion in free cash flow last year. This liquidity allows it to fund mid-sized bolt-on acquisitions, like the $2 billion Excellergy deal in March 2026, without stressing its balance sheet or taking on dangerous debt. Novartis is a premier income sanctuary. In early 2026, it proposed a dividend of CHF 3.70 per share, a 5.7% increase, yielding approximately 3%. It has a decades-long track record of uninterrupted payouts, providing a reliable paycheck for patient holders.
While we acknowledge the potential of NVS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: Israel Englander Stock Portfolio: Top 10 Stock Picks and Billionaire Stan Druckenmiller’s 10 Small and Mid-Cap Stock Picks with Huge Upside Potential.
Disclosure: None. Follow Insider Monkey on Google News.
Four leading AI models discuss this article
"Novartis is a high-quality defensive play, but its current valuation fails to account for the long-term margin erosion inherent in the evolving U.S. pharmaceutical pricing landscape."
Novartis (NVS) has successfully pivoted to a pure-play innovative medicines model, but the valuation premium is now baked in. While 40% operating margins are impressive, the reliance on a few key assets like Pluvicto and Kisqali creates a 'single-point-of-failure' risk if clinical data or competitive entrants disrupt their market share. The article ignores the looming patent cliffs and the intense pricing pressure from the Inflation Reduction Act, which will likely squeeze margins for high-growth oncology drugs over the next 3-5 years. I see NVS as a defensive compounder, not a high-growth vehicle; investors expecting tech-like scaling will likely be disappointed by the reality of drug commercialization cycles.
If Novartis successfully secures new indications for Pluvicto and maintains its dominant manufacturing lead in radioligand therapy, the company could achieve a valuation re-rating that justifies its current growth narrative despite regulatory headwinds.
"NVS offers rare pharma combo of 40%+ margins, explosive key-drug growth, and 3% yield at discount valuation, with radioligand moat underappreciated."
Novartis (NVS) post-Sandoz spin-off shines with 57% Kisqali sales growth, 42% Pluvicto ramp, and 40.1% core operating margins driving $17.6B FCF—elite capital efficiency funding acquisitions like $2B Excellergy without debt bloat. Radioligand moat via FDA-approved Millburn scaling positions it as oncology leader. 5.7% dividend hike to CHF 3.70 (~3% yield) and decades of payouts make it a defensive powerhouse. Article downplays valuation context; at ~14x forward P/E (recent levels), it trades cheap vs. 10-15% EPS growth trajectory if pipeline holds.
Pharma growth is notoriously lumpy—Kisqali faces intensifying CDK4/6 competition from Verzenio (Lilly) and Verzenat (others), while Pluvicto's supply scaling risks delays or shortages, and patent cliffs like Entresto (2025 US) could erode revenues.
"NVS is a quality compounder at fair-to-rich valuation, not a low-risk high-growth bargain—the article's framing obscures meaningful pipeline and competitive execution risk."
NVS's 57% Kisqali growth and 42% Pluvicto growth are genuinely impressive, but the article conflates recent momentum with sustainable competitive advantage. The 40.1% core operating margin is elite, yet radioligand therapy remains nascent—clinical adoption curves are unpredictable, and competitors (Eli Lilly, Roche) are aggressively entering this space. The Sandoz spin-off was strategically sound, but stripping out generics also removed a cash-generative, recession-resistant revenue stream. At a 3% dividend yield on a pharma stock, NVS is priced for perfection: pipeline execution risk, patent cliffs on legacy drugs, and geopolitical pricing pressure (EU, China) are real. The $2B Excellergy acquisition is a minor bolt-on, not transformative.
If Kisqali and Pluvicto growth rates decelerate to industry-normal 15-20% within 18 months due to market saturation or competitive entry, or if a late-stage pipeline candidate fails, the stock re-rates sharply downward—high margins don't survive pipeline disappointment in biotech.
"Novartis can sustain high margins and cash flow if Kisqali, Kesimpta, and Pluvicto deliver continued growth, but that upside is fragile and highly dependent on regulatory outcomes and competitive dynamics."
Novartis has pivoted to a higher-margin growth trajectory after the Sandoz spin-off, with Kisqali, Kesimpta, and Pluvicto driving accelerating sales and a core operating margin around 40%. Free cash flow around $17.6 billion and a steady CHF3.70 dividend support a defensive, income-friendly profile while enabling bolt-on deals. However, the article glosses over real risks: radioligand therapy remains a manufacturing-intensive niche with regulatory and payer hurdles, and Pluvicto/Kisqali growth could slow if competition or trial results disappoint. Valuation likely reflects optimistic pipeline assumptions; any delay, setback, or patent/competitive pressure could compress multiples despite the current cash-generation strength.
Regulatory and adoption risk could undercut the upside: a setback for Pluvicto or slower Kisqali label expansion could erode the growth runway and cash flow even if the current trend looks strong.
"The impending 2025 Entresto patent expiration creates a revenue gap that current pipeline growth cannot offset, making the current valuation unsustainable."
Grok, your 14x forward P/E valuation is misleadingly optimistic. You are ignoring the 'Entresto cliff'—a multi-billion dollar revenue hole hitting in 2025 that will cannibalize FCF and pressure margins. While you focus on the dividend, the market is pricing in a growth deceleration that you’ve dismissed. Unless Kisqali captures significant market share from Lilly’s Verzenio, the current multiple is unsustainable. Novartis is not a growth play; it is a value trap masquerading as an oncology innovator.
"Entresto cliff is guided for and offset by high-margin growth assets, making NVS resilient rather than a value trap."
Gemini, your Entresto cliff fixation overlooks Novartis' explicit guidance for 5%+ core sales growth through 2028, with Kisqali/Pluvicto/Kesimpta already delivering mid-teens ex-legacy. 40% margins and $17B FCF buffer the drop, funding bolt-ons like Excellergy. Not a value trap—it's a resilient compounder if pipeline hits 2-3 approvals annually. Competition in CDK4/6 is fierce, but NVS's radioligand scale is unmatched short-term.
"Novartis's post-2025 growth math only works if Kisqali/Pluvicto growth rates accelerate to offset Entresto's departure—guidance alone doesn't prove that's achievable."
Grok's 5%+ core sales growth guidance through 2028 doesn't reconcile with Entresto's cliff. Novartis hasn't disclosed how much Entresto contributes to current revenues—if it's >$1B annually (plausible for a heart-failure blockbuster), that's a 5-7% headwind Kisqali/Pluvicto must overcome just to hit flat growth, let alone 5%+. Grok's citing guidance without stress-testing it against known patent expirations. That's the real test.
"Entresto cliff is real, but NVS isn't a value trap; optionality in Kisqali/Pluvicto and Excellergy could sustain FCF if pipeline executes."
Gemini, Entresto's cliff is a legitimate headwind, but labeling NVS as a value trap may overlook pipeline optionality: Kisqali/Pluvicto growth, plus Excellergy, could sustain FCF even as Entresto decays. The real risk is late-stage failures or slower radioligand adoption, not a forced multiple contraction from a single legacy asset. Valuation should hinge on pipeline outcomes and payer dynamics, not solely on Entresto's expiry.
Panelists agree that Novartis (NVS) has successfully pivoted to a higher-margin growth trajectory, driven by Kisqali, Kesimpta, and Pluvicto. However, they disagree on the sustainability of its growth and valuation, with some citing the upcoming Entresto patent cliff and intense competition in the CDK4/6 space as significant headwinds.
The potential for Kisqali to capture significant market share from Lilly's Verzenio and the optionality of the pipeline, which could sustain free cash flow even as Entresto decays.
The upcoming Entresto patent cliff and intense competition in the CDK4/6 space, which could slow down the growth of key drugs like Kisqali and Pluvicto.